Amylyx Pharmaceuticals (AMLX) Competitors $5.23 +0.01 (+0.19%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AMLX vs. SYRE, OCUL, DAWN, TVTX, PRAX, SAVA, SNDX, SPRY, RCUS, and KURAShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Spyre Therapeutics (SYRE), Ocular Therapeutix (OCUL), Day One Biopharmaceuticals (DAWN), Travere Therapeutics (TVTX), Praxis Precision Medicines (PRAX), Cassava Sciences (SAVA), Syndax Pharmaceuticals (SNDX), ARS Pharmaceuticals (SPRY), Arcus Biosciences (RCUS), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Spyre Therapeutics Ocular Therapeutix Day One Biopharmaceuticals Travere Therapeutics Praxis Precision Medicines Cassava Sciences Syndax Pharmaceuticals ARS Pharmaceuticals Arcus Biosciences Kura Oncology Spyre Therapeutics (NASDAQ:SYRE) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation. Which has better earnings & valuation, SYRE or AMLX? Amylyx Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,589.13-$338.79M-$7.47-3.68Amylyx Pharmaceuticals$196.49M1.82$49.27M-$3.82-1.37 Does the media refer more to SYRE or AMLX? In the previous week, Spyre Therapeutics had 3 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Spyre Therapeutics and 10 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.90 beat Spyre Therapeutics' score of 0.26 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amylyx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SYRE or AMLX more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -210.01% -44.40% Amylyx Pharmaceuticals -17.86%-36.97%-29.61% Does the MarketBeat Community favor SYRE or AMLX? Amylyx Pharmaceuticals received 16 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 65.31% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSpyre TherapeuticsOutperform Votes16100.00% Underperform VotesNo VotesAmylyx PharmaceuticalsOutperform Votes3265.31% Underperform Votes1734.69% Do analysts prefer SYRE or AMLX? Spyre Therapeutics presently has a consensus price target of $48.57, suggesting a potential upside of 76.62%. Amylyx Pharmaceuticals has a consensus price target of $11.43, suggesting a potential upside of 118.52%. Given Amylyx Pharmaceuticals' higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Amylyx Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.60 Do insiders & institutionals have more ownership in SYRE or AMLX? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, SYRE or AMLX? Spyre Therapeutics has a beta of 2.9, suggesting that its share price is 190% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.7, suggesting that its share price is 170% less volatile than the S&P 500. SummaryAmylyx Pharmaceuticals beats Spyre Therapeutics on 12 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$358.51M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-1.3710.57134.3717.77Price / Sales1.82243.641,158.6875.18Price / Cash7.9522.1633.5332.53Price / Book0.815.474.674.68Net Income$49.27M$153.61M$119.07M$226.08M7 Day Performance4.18%-2.00%-1.83%-1.04%1 Month Performance12.23%-7.47%-3.62%1.04%1 Year Performance-58.62%31.80%31.63%26.28% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals4.3606 of 5 stars$5.23+0.2%$11.43+118.5%-59.5%$358.51M$196.49M-1.37200Analyst UpgradeSYRESpyre Therapeutics2.342 of 5 stars$27.50+2.2%$48.57+76.6%N/A$1.41B$890,000.00-3.68100High Trading VolumeOCULOcular Therapeutix3.961 of 5 stars$8.78-1.6%$16.71+90.4%+273.6%$1.40B$58.44M0.00267DAWNDay One Biopharmaceuticals1.9859 of 5 stars$13.62+0.7%$35.71+162.2%+12.4%$1.37B$101.95M-13.2260Positive NewsTVTXTravere Therapeutics2.9019 of 5 stars$17.86+2.7%$22.62+26.6%+210.6%$1.36B$145.24M0.00460PRAXPraxis Precision Medicines1.754 of 5 stars$73.68+1.3%$146.33+98.6%+299.3%$1.36B$2.45M0.00110SAVACassava Sciences3.9767 of 5 stars$26.05-7.0%$111.50+328.0%+59.6%$1.35BN/A0.0030SNDXSyndax Pharmaceuticals3.9967 of 5 stars$15.95+1.1%$37.18+133.1%+3.4%$1.35B$139.71M0.00110Analyst ForecastAnalyst RevisionSPRYARS Pharmaceuticals2.733 of 5 stars$13.55-1.7%$24.00+77.1%+183.5%$1.34B$30,000.000.0090Analyst RevisionRCUSArcus Biosciences2.677 of 5 stars$14.62+0.8%$34.00+132.6%+4.7%$1.33B$117M0.00500KURAKura Oncology4.0784 of 5 stars$15.91-0.3%$28.83+81.2%+66.6%$1.24BN/A-6.74142Analyst Forecast Related Companies and Tools Related Companies Spyre Therapeutics Competitors Ocular Therapeutix Competitors Day One Biopharmaceuticals Competitors Travere Therapeutics Competitors Praxis Precision Medicines Competitors Cassava Sciences Competitors Syndax Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Arcus Biosciences Competitors Kura Oncology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AMLX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
